ARIAD Presents Unique Profile of Novel Multi-Targeted Kinase Inhibitor, AP24534, Supporting Multiple Oncology Indications

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today presented, for the first time, results of studies on its novel multi-targeted kinase inhibitor, AP24534, showing efficacy and oral dosing flexibility in animal models of chronic myeloid leukemia (CML), including forms of CML caused by clinically relevant variants of the target protein, Bcr-Abl. Further, AP24534 demonstrated potent inhibition of selected additional kinase targets - the receptors for vascular endothelial growth factors (VEGFR), fibroblast growth factors (FGFR) and angiopoietin (Tie2) that control angiogenesis, and Flt3 kinase that plays a critical role in the pathogenesis of acute myeloid leukemia (AML). These findings support...

Want to see the full article?

• Purchase this article for only $3.00